Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8 USD | -5.88% | +34.66% | +11.58% |
Apr. 23 | VolitionRx Limited Launches In-Clinic in U.S. and Europe Through Antech | CI |
Mar. 26 | Transcript : VolitionRx Limited, Q4 2023 Earnings Call, Mar 26, 2024 |
Evolution of the average Target Price on VolitionRx Limited
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering VolitionRx Limited
Cantor Fitzgerald | |
Benchmark Company | |
EF Hutton | |
Maxim | |
Aegis Capital |
EPS Revisions
- Stock Market
- Equities
- VNRX Stock
- Consensus VolitionRx Limited